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Abstract
Factor H (fH) is essential for complement homeostasis in fluid-phase and on surfaces. Its two C-
terminal domains (CCP 19-20) anchor fH to self surfaces where it prevents C3b amplification in a
process requiring its N-terminal four domains. In atypical hemolytic uremic syndrome (aHUS),
mutations clustering towards the C-terminus of fH may disrupt interactions with surface-
associated C3b or polyanions and thereby diminish the ability of fH to regulate complement. To
test this we compared a recombinant protein encompassing CCP 19-20 with sixteen mutants. The
mutations had only very limited and localized effects on protein structure. While we found four
aHUS-linked fH mutations that decreased binding to C3b and/or to heparin (a model compound
for cell-surface polyanionic carbohydrates), we identified five aHUS-associated mutants with
increased affinity for either or both ligands. Strikingly, these variable affinities for the individual
ligands did not correlate with the extent to which all the aHUS-associated mutants were found to
be impaired in a more physiological assay that measured their ability to inhibit cell surface
complement functions of full-length fH. Taken together, our data suggest that disruption of a
complex fH-self surface recognition process, involving a balance of affinities for protein and
physiological carbohydrate ligands, predisposes to aHUS.
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Introduction
Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by hemolytic
anemia, thrombocytopenia and acute renal failure (1). In 1998, Warwicker et al. described
mutations in the complement regulator, factor H (fH), associated with aHUS (2). This
observation was subsequently confirmed in five independent cohorts of aHUS patients (3-7).
The majority of these mutations are heterozygous and cluster in the C-terminus of fH.
Incomplete penetrance is described in all reports, suggesting that a combination of
mutations, risk haplotypes, and precipitating factors, such as infection or pregnancy, are
required for aHUS to manifest (8-12).
Factor H, an abundant serum glycoprotein (~500 μg/ml), plays a key role in the homeostasis
of the complement system. It accelerates the decay of C3b,Bb complexes that, in the
alternative pathway, proteolytically convert C3 to its activated form, C3b (13). It is also a
cofactor for factor I-mediated cleavage and inactivation of C3b (14). Factor H is composed
of 20 complement control protein modules (CCPs) that resemble beads on a flexible string
in the transmission electron microscope (15, 16). The N-terminal four CCPs (i.e. CCP 1-4)
encompass the region capable of cofactor and decay accelerating activity (17-20). A second
principal C3b-binding site lies within the C-terminal pair of CCPs (CCP 19-20) and also
interacts with iC3b and C3d (18, 21-23). At least two sites on fH (i.e. CCP 7 and CCP 20)
interact with heparin and other polyanions (24-30). The C-terminal site additionally binds
sialic acids (24, 28).
In the absence of fH, spontaneous activation of the alternative pathway of complement
occurs in plasma, which leads to consumption of complement components C3 and factor B.
In addition to its function as a regulator of alternative pathway activation in fluid phase, fH
is essential for complement control on many self-surfaces. For example, it binds to human
endothelial cells and basement membranes (31) protecting them from complement-mediated
attack (32). Indeed, fH has a ten-fold higher affinity for C3b on host cells and other non-
activators of complement versus activators, which is dependent on the presence of sialic acid
clusters or other polyanions on the surface (33, 34). The specific chemical nature of human
host markers has not been identified, but it is assumed to be polyanionic since sheep cells,
which do not activate complement, activate the alternative pathway after surface sialic acid
is removed (33, 34). Previous studies have shown that the C3b- and polyanion-binding sites
in CCPs 19-20 are key for fH interactions with host surfaces (21, 22, 28, 31, 35-37).
Furthermore, a recombinant form of these C-terminal CCPs (rH19-20) has been shown to
compete with full-length fH for binding to C3b and host polyanions (35). This competition
results in increased complement activation on host surfaces, without affecting control of
complement in plasma (35).
The C-terminal module of fH is the most commonly mutated one in individuals with aHUS
and functional analysis to date has demonstrated an associated impairment of binding to C3b
and/or GAGs (38). Moreover, a transgenic mouse line expressing fH missing its C-terminal
region regulated C3 activation in plasma but spontaneously developed aHUS (39). The
truncated murine fH failed to bind to endothelial cells. Thus, in aHUS, the mutant form of
fH is believed to regulate the alternative pathway of complement in the fluid phase, but fails
to be recruited by glomerular endothelial cells and/or the glomerular basement membrane.
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Controversy has arisen over the interpretation of the limited structure-function studies that
attempted to assign disease-linked mutations in the fH C-terminus to binding sites on the fH
C-terminus for specific ligands. Jokiranta et al. (40) concluded that aHUS-linked mutations
lie in a C3d/b-binding site while the polyanion-binding site is not affected. On the other
hand, Herbert et al. (41) presented evidence that shows that mutations cluster within an
electropositive polyanion-binding site. Moreover, none of the disease-linked mutants have
been analyzed with respect to their structural integrity; thus it remains possible that the
mutations are destabilizing or result in unfolded protein. In the current work we set out to
resolve these issues and to thereby address the question: why do aHUS-linked mutations
prevent fH from functioning properly?
To avoid difficult-to-interpret complications likely to arise from the presence of additional
C3b- and heparin-binding sites that reside within the N-terminal 18 CCPs of fH, we mutated
and analyzed a recombinant construct containing only the CCPs 19 and 20 (rH19-20). We
measured the affinity of each of sixteen rH19-20 mutants for C3b and, separately, for
polyanions. Because C3b and host polyanions reside together on surfaces, we also used
assays designed to measure the interactions with these ligands simultaneously in a
physiological setting on the cell surface.
Materials and Methods
Red blood cells and buffers
Blood from sheep and from two healthy human adults was collected by venipuncture and the
red cells were frozen at −80°C (42). The University of Texas Health Science Center
institutional review board approved protocols, and written informed consent was obtained
from all human donors. The buffers used were: PBS (10 mM sodium phosphate, 140 mM
NaCl, 0.02% NaN3, pH 7.4); veronal buffered saline (VBS), 5 mM veronal, 145 mM NaCl,
0.02% NaN3, pH 7.3; GVB, VBS containing 0.1% gelatin; GVBE, GVB containing 10 mM
ethylenediaminetetraacetic acid (EDTA); DGVB, half-physiological ionic-strength buffer
prepared by diluting GVB two-fold with 5% dextrose in water; MgEGTA, 0.1 M MgCl2, 0.1
M EGTA (ethyleneglycoltetraacetic acid), pH 7.3.
Purified proteins
Complement proteins fH (43), C3 (44, 45), factor B (46), and factor D (47) were purified
from normal human plasma as described. A fragment consisting of C-terminal residues
1107-1231 of fH (domains 19-20, i.e. rH19-20) was cloned, expressed and purified as
described (41). Site directed mutagenesis was used to generate sixteen mutant versions of
rH19-20, using the QuickchangeR mutagenesis system (Stratagene, Cedar Creek, TX). Ten
of these are associated with aHUS (D1119G, R1182S, W1183R, T1184R, L1189F, L1189R,
S1191L, R1210C, R1215G, and double mutant S1191L;V1197A) (48); the remaining six
mutants (E1172R, K1188Q, R1203S, R1203Y, R1210S, and K1230A) have not so far been
observed in aHUS patients, but were generated to probe C3b- and polyanion-binding sites.
The residues chosen for the design of these mutants lie in putative C3b- and polyanion-
binding sites (40, 41) and cover a wider surface region within domain 20, which is where
most aHUS-associated mutations in fH lie. The proteins were cloned and expressed using
the Pichia pastoris strain KM71H as previously described (41). Mass spectra of recombinant
proteins (purified by cation-exchange chromatography and stored at −80°C in PBS as
described previously (41)) were consistent with predicted molecular weights. A 15N-labelled
sample of each mutant was prepared by using (15NH4)2SO4 (Isotec) as the sole source of
nitrogen during cell growth. Protein concentrations were determined (280 nm) using
theoretical E1%1 cm values (49). Factor H and an aliquot of wildtype rH19-20 (100 μg) were
radiolabeled with 125I to specific activities of 4 to 6 μCi/μg as described (35).
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Nuclear magnetic resonance (NMR) methods
For NMR, samples of 15N labeled proteins were 100 μM in 20 mM deuterated sodium
acetate, 10% D2O, pH 4.5. In each case a [15N,1H] heteronuclear single quantum coherence
(HSQC) spectrum was collected at 37°C on a Bruker AVANCE 800 MHz spectrometer
fitted with a 5 mm CPDCI cryoprobe with Z gradients. Based on existing spectral
assignments for wild type rH19-20 (41), analyses were conducted to reveal any changes in
the 15N and 1H chemical shifts of each backbone amide consequent upon mutagenesis.
Heparin affinity chromatography
Protein samples (3 μM, 1 ml) in 20 mM potassium phosphate buffer, pH 7.4, at 20°C, were
loaded individually onto a HiTrap heparin-affinity chromatography column (7 mm × 25 mm,
GE Healthcare, Piscataway, NJ), equilibrated with the same buffer, and subsequently eluted
with a 20-column volume gradient from 0–1 M NaCl in 20 mM potassium phosphate buffer,
pH 7.4. Protein elution was monitored using absorbance at 280 nm. Similar experiments
were carried out for the aHUS-associated mutants (0.6 μM, 5 ml) in 20 mM HEPES, pH 7.0,
at 4°C, and eluted with a 20 column volume gradient from 0-1 M NaCl in 20 mM HEPES,
pH 7.0.
Gel-mobility shift assays (GMSA)
Oligosaccharides were prepared for GMSA from low-molecular weight heparin by partial
digestion with heparinase I followed by size-fractionation on a BioGel P10 gel-filtration
column (BioRad, Hercules, CA) (50). In the case of the tetrasaccharide, dp4, strong anion-
exchange chromatography (AS-17 Ionpac, Dionex, Sunnyvale, CA) was subsequently
performed to isolate only fully sulfated product (ΔUA2S-GlcNS6S-IdoA2S-GlcNS6S). Due
to the heterogeneity associated with the length of the hexasaccharide (dp6) this purification
step was omitted in dp6 preparations resulting in variable sulfation patterns. Fluorophore-
labeled species were produced by attachment of 2-aminoacridone to the oligosaccharide
reducing end (50), and GMSAs were performed, as described previously (51).
Analysis of C3b binding by surface plasmon resonance (SPR)
A BIAcore 3000 instrument was used to perform SPR. Human C3b (800-2000 response
units (RU)) was amine coupled to a CM5 sensor chip (GE Healthcare). In addition, a
streptavidin (SA) sensor chip (GE Healthcare) was coated with biotinylated C3b, generated
as recently described (52). For each type of sensor chip, three flow cells (Fc2, Fc3 and Fc4)
were independently coupled with C3b. Then 20 μl injections of the rH19-20 mutants and
wildtype rH19-20 were performed at 0-12 μM over the flow cells at 5 μl/min, at 22°C. The
running and sample buffer consisted of PBS with 0.005% Tween. The maximum
equilibrium binding of the proteins to C3b was measured by subtracting RUs obtained for
the reference cell (Fc1) from the C3b-coupled flow cell RUs. The equilibrium binding
values for each concentration were plotted using the Grafit 5 program (Erithacus), which
determined the apparent Kd by fitting the data to a single-site saturation curve. Since the
wildtype rH19-20 interacts with C3b with a 1:1 stoichiometry, the Kd values of the mutant
proteins were calculated by setting the capacity (as a constant) to that of the average (n=12)
capacity of wildtype rH19-20, for each C3b-coupled sensor chip.
Preparation of C3b-coated cells and zymosan particles—Deposition of C3b on
sheep erythrocytes (ES), and zymosan particles (Sigma-Aldrich, St. Louis, MO) was
accomplished using purified C3, factor B and factor D as previously described (53). The
number of bound C3b molecules was determined to be 125,000 per Es cell or 100,000 per
zymosan particle by measuring binding of radiolabeled factor Bb (53).
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Binding assays with C3b-coated cells and zymosan
Sheep erythrocytes (ESC3b) bearing a total of 1 μg C3b were incubated with ~20 ng of
radioiodinated human fH and 0 to 8 μM non-labeled rH19-20 (wildtype or mutants) in 100
μl half-ionic strength buffer (DGVB). Alternatively, the cells were incubated with ~20
ng 125I-rH19-20 and the non-labeled proteins. After 20 min at 22°C, the bound and free
radiolabeled proteins were separated as described (34). The competition experiments with
C3b-coated zymosan (ZymC3b) were carried out as described above, except only the IC50
dose of the unlabeled wildtype rH19-20 (1 μM) was compared to a 1 μM dose of various
rH19-20 mutants.
Hemolysis assays
Lysis of human erythrocytes (35) (EH) was measured by pre-incubating 5 × 106 EH with 7
μg/ml anti-CD59 monoclonal antibody (clone MEM43; Abcam, Cambridge, MA) for 20
min at 4°C, and then mixing, on ice, with GVB, normal human serum (NHS; 40% final),
and 0.1 M MgEGTA (5 mM final concentration) in the presence of 1 μM wildtype or
mutant rH19-20. This concentration of wildtype rH19-20 is enough to achieve ~50%
hemolysis (IC50) of anti-CD59 treated cells, due to inhibition of fH-mediated protection.
The mix was immediately transferred to a 37°C water bath and incubated for 20 min. To
determine the extent of hemolysis induced by the mutants versus the wildtype rH19-20, 200
μl cold GVBE was added, the samples were centrifuged, and the optical density of the
supernatant was determined at 414 nm. The percent lysis was determined by subtracting the
A414 of the background lysis control, and dividing by the maximum lysis in water.
Statistical analysis
Conventional Student's t tests (2-tailed) were used to assess the statistical significance of the
difference between wildtype rH19-20 and the mutants in their ability to bind to C3b
(BIAcore), to C3b on zymosan, and to lyse EH in the presence of NHS and p values <0.05
were considered statistically significant.
Results
A panel of mutant recombinant forms of fH domains 19-20 (rH19-20) was expressed in P.
pastoris
A total of sixteen mutations of rH19-20 were expressed in P. pastoris, as summarized in
Figure 1A. Ten of these correspond to aHUS-linked sequence variants (38). As previously
noted (41) these, to a large extent, congregate on one face of module 20 (Fig. 1A). A further
six mutants, that have not been identified in aHUS patients, but that cover a wider surface
region of the disease-linked domain 20, were designed to help delineate binding sites for
C3b and heparin. Based on previous studies (40, 41), the residues chosen for these
“designer” mutants are hypothesized to lie within C3b- or polyanion-binding sites. All the
mutants were homogeneous as judged by SDS-PAGE under both oxidizing and reducing
conditions (not shown). The expected molecular weight of all the mutants was confirmed by
electrospray ionization mass spectrometry (not shown).
The aHUS-linked mutations do not perturb structure
Samples of wildtype-sequence rH19-20, and of the mutant forms, were isotopically enriched
with 15N. Each sample was used to collect a 2D 15N,1H-HSQC spectrum. Nearly every
amino acid residue within wildtype rH19-20 yielded a distinct peak in such a spectrum, as
reported previously (41) and as expected for a properly folded polypeptide. For fifteen out of
sixteen mutants, the 15N,1H-HSQC spectra (not shown) were also consistent with folded
proteins; the exception was the designed mutant R1203Y, which was judged to be unfolded
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by 1H NMR. Furthermore, a comparison of HSQC spectra showed good conservation of
chemical shifts with variations confined to the vicinity of the mutated residues. Moreover,
lineshapes and spectral quality were consistent with monomeric protein for all proteins
tested. These observations suggest that none of the aHUS-linked mutations resulted in major
structural changes.
The aHUS-linked mutants bind with varying affinity to heparin
Previous work suggests that host GAGs form at least part of the target recognized by the C-
terminal anchoring region of fH (25, 28, 31, 35, 37, 41). Thus it was of interest to assess the
extent to which our mutations affect GAG binding. Heparin is commonly used as an
experimental model compound for GAGs that are found on cell surfaces such as heparan
sulfate and dermatan sulfate. The wildtype and mutant forms of rH19-20 were loaded onto a
heparin-affinity column and eluted using a salt gradient (Fig. 2A-B). Some aHUS-linked
mutants bound to the resin more tightly, others bound more weakly and the remainder eluted
similarly to wildtype rH19-20. For example, the strongest interaction was found with
W1183R (eluting at 520 mM NaCl), while the weakest was R1182S (eluting at 325 mM
NaCl). The wildtype rH19-20 eluted at 370 mM NaCl. In general, mutations that resulted in
gain of positive charge increased affinity (aHUS mutants W1183R, T1184R, L1189R;
designed mutant E1172R), while mutations causing a loss of positive charge decreased
affinity (aHUS mutants R1182S, R1210C, R1215G; designed mutants K1188Q, R1203A,
R1210S, K1230A). To investigate further, GMSAs were performed. In these assays, the
migration of a fluorescently tagged defined-length GAG fragment through an agarose gel
was monitored in the presence of wildtype rH19-20 or the mutants. The wildtype protein
binds and hence retards the mobility of both a chemically pure fully sulfated heparin-derived
tetrasaccharide (dp4, data not shown), as well as heparin-derived hexasaccharides (dp6) that
contain heterogeneous sulfation patterns (Fig. 2C). The experimental conditions were
optimized so that the wild type showed some free dp6 migrating towards the anode. Smaller
amounts of observed free dp6 for some mutants indicated stronger binding, while larger
amounts corresponded to weaker binders. The ranking of affinities of rH19-20 mutants
(aHUS-associated and designed mutants) for GAGs, as inferred from the GMSA (Fig. 2C),
was very similar to the ranking derived from heparin-affinity chromatography (Fig. 2A-B).
In summary, there is no uniform link between the affinity for heparin of the aHUS-
associated mutants and aHUS pathology. Thus, some of the aHUS-associated mutants
(W1183R, T1184R, L1189R, L1189F, S1191L, and S1191L;V1197A) were either
unaffected or had increased affinity for heparin.
The aHUS-linked mutants bind with varying affinity to C3b
We measured the affinity of each mutant protein for C3b using SPR. C3b was immobilized
on a CM5 sensor chip by amine coupling. Figure 3A summarizes the value of Kd obtained
for each mutant. Four of the aHUS mutants (D1119G, R1182S, R1210C, and R1215G)
bound with lower affinity to immobilized C3b, compared to the wildtype. The other aHUS
mutants were either unaffected in their ability to bind (V1197A in the context of the
S1191L;V1197A double mutant) or had a slightly (L1189F) or significantly (W1183R,
T1184R, L1189R, S1191L) increased affinity for C3b. It is noteworthy that most of the
aHUS mutants that clearly bind more strongly to C3b (i.e. W1183R, T1184R, L1189R)
correspond to those with a higher affinity for heparin, while most of those with low affinity
for C3b (i.e. R1182S, R1210C, R1215G) correspond to those exhibiting weaker heparin
binding, as summarized in Figure 4. Interestingly, the aHUS mutant S1191L, which bound
with greater affinity to C3b (Fig. 3-4), maintained a normal ability to bind heparin (Figs. 2
and 4).
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A second type of sensor chip, pre-immobilized with streptavidin (SA chip), was used to
immobilize C3b molecules that had been biotinylated at the cysteine-SH within the thioester
site. This mode of immobilization emulates more closely the natural orientation of C3b on
surfaces (52). Figure 3C shows representative equilibrium binding single-site saturation
curves for rH19-20 wildtype as well as examples of a high-affinity (L1189R) and a low-
affinity (R1215G) mutant binding to C3b. The Kd values obtained with the SA-C3b sensor
chip (Fig. 3B) were very similar to those obtained on the CM5 chip (Fig. 3A). These
findings indicate that the mode of C3b coupling did not bias the measured Kd values.
In order to further investigate the unexpected increase in affinity for C3b of some mutants as
observed by SPR, C3b-coated zymosan particles (ZymC3b; which are devoid of polyanions)
were incubated with radiolabeled wildtype rH19-20 in combination with unlabeled wildtype
or the mutants with the highest and lowest affinity for C3b (by SPR). Figure 3D shows that
aHUS mutants W1183R, T1184R, and L1189R as well as designed mutant E1172R,
competed with radiolabeled rH19-20 more efficiently for binding to surface-bound native
C3b than the unlabeled wildtype rH19-20, while aHUS mutants R1182S and D1119G were
less efficient. The differences between the ability of the wildtype versus each of the mutants
to bind to ZymC3b were all significant (p<0.05). These results agree with the SPR data,
confirming that some disease-linked mutants do indeed bind with higher affinity to C3b.
Taken together, the C3b-binding data show that there is no correlation between affinity for
C3b and the association of the mutations with aHUS.
Delineating C3b and heparin binding sites
Considering our panel of sixteen rH19-20 mutations as a whole, fourteen neither introduced
a cysteine (the exception being R1210C) nor resulted in structural disruption (the exception
being R1203Y). Of these fourteen, nine had a positive or negative effect, compared to
wildtype rH19-20, on both heparin and C3b binding, while one (V1197A, within the context
of S1191L;V1197A double mutant) had no significant effect (Fig. 4). Two other mutations
(R1210S and K1230A) decreased heparin binding, but did not alter C3b binding. Mutant
D1119G significantly decreased C3b binding, but had no effect on heparin binding. On the
other hand, S1191L increased C3b binding, while having no effect on heparin binding. Since
these mutations resulted in only localized structural changes it seems valid to summarize
their various functional consequences on the 3D structure of wildtype rH19-20 (Fig. 1B) and
to infer that the wildtype residue is directly involved in ligand-binding if its substitution
alters affinity. On this basis, Figure 1B illustrates that there is an overlapping binding patch
on one face of module 20 for heparin and C3b. Two of the mutants that had minor or
negligible effect on heparin binding (L1189F and V1197A, respectively) both involve
conservative substitutions of buried side chains.
The rH19-20 aHUS-associated mutants are impaired in their ability to bind to C3b-coated
host-like erythrocyte surfaces
A clear message of the results described above is that while ten mutants included in this
study have been linked with occurrence of aHUS (48), not all of them are negatively
affected in their ability to bind to C3b and polyanion ligands (summarized in Fig. 4). We
therefore tested whether these mutations interfere with the ability of fH to bind,
simultaneously, to C3b and host-like polyanions in a more physiological setting using a
competitive binding assay, as previously described (35). In this assay, rH19-20 competes
with radiolabeled full-length fH, inhibiting its binding to C3b and host-like polyanions on
sheep erythrocytes (ES), which carry high levels of sialic acid-containing polysaccharides
(33, 34) (as do most human cells and tissues). We showed previously that such competition
impairs fH complement-regulatory functions and increases complement activation on host
surfaces (35). Thus, the C-terminal module-pair is important for anchoring fH to self-
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surfaces following C3b deposition. Data in Figure 5A confirms that wildtype-sequence
rH19-20 inhibits, in a dose dependent manner, the binding of full-length fH to C3b-coated
host-like cells, with an IC50 of 0.2 μM. The aHUS-linked mutant forms of rH19-20, on the
other hand, were significantly impaired in their ability to compete, displaying from < 2.5%
(R1215G, D1119G and R1182S) to 40-50% (T1184R and R1210C) of the inhibitory activity
of the wildtype rH19-20 (Fig. 5A). Only the designed mutant (E1172R) retained more than
70% activity in this assay. The presence of the V1197A mutation within the double mutant
S1191L;V1197A did not further impair its ability to compete versus S1191L alone.
We also determined the effect of the mutations on the ability of rH19-20 to compete with
radiolabeled wildtype rH19-20, i.e. without the potential interference of the other C3b/
polyanion-binding sites or higher-order architecture of full-length fH, and very similar
results were obtained (Fig. 5B). Thus, the four aHUS mutants that were most affected
(D1119G, R1182S, W1183R, and R1215G) and the two least affected mutants (T1184R and
R1210C) in the competition assay with full-length 125I-fH, ranked comparably in the
competition assay with 125I-rH19-20, and can be compared in summary Figure 4.
Ability of rH19-20 aHUS-associated mutants to inhibit fH-mediated protection of human
erythrocytes from complement-mediated lysis
Experiments were performed in which complement-mediated lysis of human erythrocytes
was measured in the presence of normal human serum and rH19-20 mutants (Fig. 6).
Wildtype rH19-20 competes with fH, inhibiting fH-mediated protective action more
effectively than any of the aHUS-linked mutants, apart from R1210C and T1184R, which
are comparably effective. This is largely consistent with the cell-surface binding results (Fig.
5) and provides further evidence that anchoring of fH to self-surfaces via its C-terminus is
essential for its protective function.
Thus, the competition data strongly indicate that a common feature of aHUS-linked fH
mutants is the reduced ability to engage, in a functionally effective way, with the fH target
(C3b/C3d), when in the context of polyanion-rich self-surfaces. Intriguingly, this behavior
on physiological cell surfaces does not correlate with the increased affinity that some of the
aHUS mutants displayed for C3b (Fig. 3) and/or for the GAG-model compound heparin
(Fig. 2), when these interactions were analyzed individually.
Discussion
If a mutation were to impair the ability of fH to regulate complement at self-surfaces it
would have particularly significant consequences for tissue and cell surfaces thought to rely
on fH for protection from complement-mediated damage. An example is the glomerular
basement membrane that lacks membrane-bound complement regulators, but is exposed to
plasma (and therefore the alternative pathway of complement), by fenestrations between the
endothelial cells of the glomerular microvasculature. Thus, fH mutations clustered within
the surface-anchoring C-terminal region, which have been detected in a significant
proportion of aHUS patients, may be expected to directly trigger or exacerbate pathogenesis.
Understanding the precise properties of disease-linked mutants of fH will therefore help to
clarify the molecular basis of aHUS. For example, disease-associated mutations in the C-
terminal region may disrupt its three-dimensional protein structure. Alternatively, they could
interfere with the recognition site in CCP 20 of fH for polyanionic self markers, or they may
perturb the C-terminal binding site for surface-bound C3b, or they could affect both
polyanion and C3b-binding sites simultaneously. In the present study, we sought to
distinguish between these various possibilities.
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Our NMR analyses show that none of the ten disease-linked mutations in the current study
result in anything other than highly localized effects on the structures of CCPs 19 or 20.
Consequently, any functional effects of these mutations may reasonably be ascribed to their
location within, or near to, critical binding sites on the wildtype protein. C3b- and heparin-
binding data collected on these and five further, structurally intact, “designer” mutations in
the context of rH19-20 allow the most comprehensive delineation of binding sites for these
ligands to date. This exercise (summarized in Figs. 1B and 4) suggests that positively
charged binding sites for heparin and C3b overlap on one face of rH19-20. The binding
surface for heparin (and by extension, for other glycosaminoglycans) appears to extend
towards the C-terminus of fH while the C3b-binding surface extends into module 19.
Changes in the electrostatic nature of the surface had the largest influences (gain of positive
charge or loss of negative charge appeared to correlate with increases of both heparin and
C3b-binding), thus it is possible that some of the residues concerned are involved in
electrostatic steering effects rather than direct contacts with ligands. These findings are in
partial agreement with previous reports (40, 41) but do not support a suggestion of
simultaneously occupied binding sites on opposite faces of CCP 20 (41).
Functional analyses of some aHUS-associated mutants reveal effects consistent with an
intuitively feasible model of aHUS pathogenesis; i.e. their reduced ability to bind to a
polyanion-rich C3b-coated host-like surface correlates with their diminished performance in
assays that measure directly affinity for C3b or for heparin. For example, although D1119G
(involving loss of a negative charge) is unaffected in its ability to bind heparin, it has
significantly diminished affinity for C3b (Fig. 3-4) and this mutant was also the weakest of
all the mutants in the cell surface assays. Moreover, analysis of some of the “designer”
mutants (i.e. those engineered for this study to help delineate C3b- and heparin- binding
sites, but not identified in any aHUS patients to date) also produced results that appear to
link an affinity for C3b and/or heparin to a capacity for blocking fH binding to a C3b-coated
erythrocyte surface. Thus, the designer mutant R1210S binds C3b with wildtype affinity and
is only slightly diminished in affinity for heparin, while maintaining near-wildtype activity
in the cell surface assay. The case of the aHUS-linked R1210C is complicated by the
likelihood that it forms disulfide bonds with itself or other proteins (54) (recombinant
R1210C was found to be glutathionylated in our study). In all, seven mutations (aHUS-
linked mutants R1215G and R1182S, and designer mutants K1188Q, R1203S, R1210S,
K1230A) display both weaker heparin and C3b binding (Figs. 2-3) and, as expected, their
performance is significantly impaired in the cell-surface assays (Fig. 5). It should be noted
that the reduced heparin binding obtained with R1182S contrasts with the unaffected heparin
binding previously observed with a mutant, R1182A, which has not been found in aHUS
patients (40).
Indeed all the aHUS-associated mutants exhibit a weaker than wildtype ability to compete
with fH for erythrocyte surface binding (Fig. 5). For example, L1189R and W1183R
perform very poorly in cell-surface assays (Fig. 5-6), while T1184R and R1210C are the
only aHUS-mutants that are nearly as good at inhibiting the protective effects of fH as the
wildtype rH19-20. What is striking is that several of these mutations have a higher affinity
both for heparin (Figs. 2 and 4) and for C3b (Fig. 3-4). Such is the case for aHUS mutants
W1183R, T1184R, L1189R, and the designer mutation E1172R, all of which involve an
introduction of one or more positive charges. Note that in the case of the W1183R mutant,
the observed increased affinity for C3b and heparin differed from what had been observed
previously with another aHUS-linked mutant, W1183L (40) that had reduced binding to C3b
and heparin; unlike W1183L (40), the W1183R mutant ran as a single band by SDS-PAGE
(not shown). The L1189F mutation also shows increased C3b- and heparin-binding, albeit to
a much lesser extent than L1189R (Figs. 3-4). Another mutant (S1191L) with weaker than
wildtype activity in the cell surface assays (Figs. 5-6), has enhanced affinity for C3b (Fig.
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3), contrary to previously reported results (54, 55). This same mutant had no effect on
heparin binding (Fig. 2), in agreement with a previous study (55). Interestingly, the presence
of V1197A in the S1191L;V1197A double mutant has no additional effect in any of the
assays tested versus the S1191L mutant.
An overall summary of the heparin and C3b binding results (where a wide range of affinities
for C3b and heparin were observed), and the cell-surface complement functional assays
(where all aHUS-linked mutants were impaired), is illustrated in Figure 4. Taken together
these results unexpectedly show that, measured separately, affinities for C3b and heparin do
not correlate consistently with the strength of binding to a polyanion-rich erythrocyte
surface (on which C3b has been deposited); nor do they correlate with the disease-risk
phenotype.
In the case of heparin it is conceivable that this material is not in fact representative of a
putative host tissue-specific polyanionic ligand. The presence in such a ligand of particular
patterns or densities of sulfation, for example, might result in differential binding amongst
the mutants that correlates better with cell-surface assays. Studies aimed at identifying
physiological polyanion species, as well as elucidating their chemical nature, are warranted.
The lack of correlation between the separate ligand binding assays and the cell based assays
also suggests that a mutation may affect a third functional site in CCPs 19-20, perhaps
different from those involved in C3b or polyanion binding. For example, a mutation could
affect the region involved in the formation of putative dimers or tetramers (40, 56-58),
which may be important for fH binding/function on the cell surface. In this regard, we have
recently determined that polyanions greatly promote formation of fH dimers and tetramers,
and that this dimerization/tetramerization leads to an increase in fH binding and complement
control activity at the cell surface (58). In addition, we have determined that this polyanion-
induced self-assembly is mediated, at least in part, by C-terminus to C-terminus complex
formation, specifically through CCP 18-20 (58).
A further possibility derives from consideration of the relative affinities of fH for each
ligand in the setting of the cell surface, and the order of binding events. An increased
affinity between fH and polyanions, due to CCP 19-20 mutations, may result in a decrease in
the ability of fH to diffuse normally over the cell surface, impairing its ability to efficiently
encounter and bind C3b. Thus, such mutants would be less effective than normal CCP 19-20
that binds with the correct affinity to the combination of both ligands (polyanions and C3b/
C3d). Likewise, the mutants that were found to have increased affinity for C3b may get
retained/delayed in complexes with the products of decay acceleration and cofactor activity
(i.e. C3b/iC3b).
Thus, we propose that aHUS-linked mutations disturb a complex relationship between
affinities of fH for its individual ligands (C3b and physiological polyanions) or possibly for
itself, in the context of the cell surface.
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CCP complement control protein domain
rH 19-20 recombinant domains 19-20 of factor H
GAG glycosaminoglycans
VBS Veronal-buffered saline
GVB VBS containing 0.1% gelatin
GVBE GVB containing 10 mM EDTA
MgEGTA equimolar MgCl2 and EGTA
NHS normal human serum
GMSA gel mobility shift assay
dp6 hexasaccharide
SPR surface plasmon resonance
RU response unit
EH human erythrocytes
ESC3b C3b-coated erythrocytes
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FIGURE 1.
Summary of mutagenesis study mapped onto 3-D structure of fH CCP 19-20. A, Side-chain
heavy atoms of disease-linked mutations (left-hand panel) or non-disease linked mutations
are drawn (in various colors for clarity) on cartoon representations of fH CCP 19-20.
*V1197A was made in the context of the double mutant - V1197A;S1191L. B, A surface
representation of mutated residues is superimposed on the structure (orthogonal views are
shown; left-hand view is identical to that in A) and color-coded (see key) according to the
predominant impact of the mutation on ligand binding. Positive and negative effects were
not discriminated - “Heparin only” implies that the effect on C3b-binding was small while
“C3b only” implies a small effect on heparin binding. The cyan color indicating “small
effect” refers to that of L1189F on C3b and heparin binding. L1189R had significantly
increased binding to both C3b and heparin.
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FIGURE 2.
Affinities of wildtype and mutant rH19-20 for glycosaminoglycans. Variants of rH19-20
were eluted from a HiTrap heparin-affinity chromatography column and protein elution was
monitored using absorbance at 280 nm (A). In (A), left panel, for clarity, only the elution
profile of the aHUS-associated mutant with the highest (W1183R) and the lowest (R1182S)
affinity for heparin are shown in comparison to wildtype rH19-20. The conductivity values
at which the aHUS-associated mutants eluted are summarized in (B), left panel. In (A), right
panel, only the elution profile of the designed mutant with the highest (E1172R) and the
lowest (R1203S) affinity for heparin are shown in comparison to wildtype rH19-20. The
conductivity values at which all the designed mutants eluted are shown in (B), right panel.
C, GMSA results. For these assays, 2-aminoacridone-tagged heparin-derived
hexasaccharides were combined with rH19-20 or its mutants to give 34 μM protein and 40
μM oligosaccharide in 12 μl PBS containing 5 mM EDTA. To these samples were added
0.5 μl of glycerol and a trace of phenol red before incubation (15 minutes, room
temperature). Samples were then loaded on a 1% agarose gel in 10 mM Tris-HCl, pH 7.4,
and 1 mM EDTA. Electrophoresis was performed (120 mV, 5 min) in a horizontal agarose
electrophoresis system, using an electrophoresis buffer (40 mM Tris/acetate, 1 mM EDTA,
pH 7.4). Immediately thereafter, the fluorescent oligosaccharides were visualized. The left
and right-hand panels show the data obtained with the aHUS-associated mutants or the
designed mutants, respectively. All results are representative of two separate experiments.
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FIGURE 3.
Binding affinity of the rH19-20 mutants for C3b. A, Kd values for the binding of rH19-20 to
C3b were measured on a CM5 sensor chip using surface plasmon resonance. Assays were
performed on a BIAcore 3000 instrument by immobilizing 800-2000 response units (RU) of
human C3b to three independent flow cells of a CM5 chip, using amine coupling. The
rH19-20 mutants or wildtype rH19-20 were injected at 0-12 μM over the flow cells. The
maximum equilibrium binding, at each concentration, was plotted using the Grafit 5
program, which determined the apparent Kd by fitting the data to a single-site saturation
curve, where the capacity was fixed (as a constant) to that of the average (n=12) wildtype
rH19-20 capacity. The standard deviations correspond to the Kd values obtained when
samples were injected over the three different C3b-coated flow cells. B, Same as panel A,
except biotinylated C3b was used to coat a streptavidin sensor chip. The non-significant
(n.s.) differences between the ability of the wildtype rH19-20 versus each of the mutants to
bind to C3b (p>0.05) are indicated. C, Representative equilibrium C3b-biotin binding curves
for rH19-20 wildtype as well as a high binding (L1189R) and a low binding (R1215G)
mutant. D, Analysis of the ability of rH19-20 mutants to compete with radiolabeled wildtype
rH19-20 for binding to C3b on zymosan particles. Zymosan particles bearing 1 μg C3b were
incubated with ~20 ng 125I-rH19-20 (wildtype) in combination with the IC50 dose of
unlabeled wildtype rH19-20 (1.5 μM) or with 1.5 μM of the rH19-20 mutants in 100 μl
DGVB. After 20 min at 22°C, the bound and free radiolabel were separated by
centrifugation of cells through 20% sucrose in DGVB. The average (n=4) percent of 125I-
rH19-20 remaining bound to the zymosan-C3b (ZymC3b) and standard deviations are
shown for each protein. The differences between the ability of the wildtype versus each of
the mutants to bind to ZymC3b were all significant (p<0.05). The results shown are from
one of two representative experiments.
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FIGURE 4.
Summary figure of relative affinities of rH19-20 wildtype and mutant proteins for C3b and
heparin, and of complement functional cell-based assays. The salt concentration (mM NaCl)
at which the rH19-20 wildtype or mutant proteins eluted from the heparin affinity column
are graphed on the x-axis. The relative affinity of the mutants versus the wildtype (WT)
protein for C3b is graphed on the y-axis using the formula: relative affinity = [(Kd of WT
rH19-20) / (Kd of each rH19-20 mutant)]. The average of the Kd values obtained on the
C3b-coated CM5 and SA sensor chips were used. The higher values represent higher affinity
for each ligand, while lower values represent the opposite. The symbols that represent each
mutant depend on their % of remaining wildtype activity in the cell-based assay that
measured the ability of the mutants to inhibit fH binding to C3b-coated host-like cells (Fig.
5A). These values are in agreement with the results obtained in the EH lysis assay (Fig. 6).
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FIGURE 5.
The rH19-20 mutants are impaired in their ability to bind to C3b-coated host-like
erythrocyte surfaces. A, Binding of radiolabeled fH to C3b on ESC3b cells in the presence of
unlabeled wildtype or mutant rH19-20. Cells bearing 34 × 1011 C3b (1 μg) were incubated
with ~ 20 ng of radioiodinated human fH and 0 to 8 μM of non-labeled wildtype or mutant
rH19-20, in 100 μl DGVB. After 20 min at 22°C, the bound and free radiolabel were
separated by centrifugation of cells through 20% sucrose in DGVB. The results are graphed
relative to the initial binding observed with labeled fH in the absence of the rH19-20
proteins. Each experiment was carried out with five proteins at a time, using wildtype
rH19-20 as an internal control in each set of assays. The average (n=5) wildtype rH19-20
IC50 is shown and was 0.20 +/− 0.04. The percent of inhibitory activity remaining for each
protein is shown in parenthesis and was calculated using the following formula: (IC50
wildtype rH19-20 / IC50 mutant rH19-20) × 100. B, Same as above, except the C3b-coated
cells were incubated with radioiodinated rH19-20 instead. The average wildtype (n=3)
rH19-20 IC50 was 0.04 +/− 0.01. The left and right-hand panels in A-B show the data
obtained with the aHUS-associated mutants or the designed mutants, respectively.
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FIGURE 6.
Ability of rH19-20 mutants to inhibit fH-mediated protection of human erythrocytes from
complement-mediated lysis. Lysis of human erythrocytes (EH) was measured by pre-
incubating anti-CD59-treated EH (5 × 106) with 1 μM wildtype or mutant rH19-20, in the
presence of 40% NHS. This concentration of wildtype rH19-20 is enough to achieve ~ 50%
hemolysis (IC50) of anti-CD59-treated cells, due to inhibition (by rH19-20) of fH-mediated
protection. The mixture was incubated for 20 min, at 37°C. To determine the extent of
hemolysis induced by the mutants versus the wildtype rH19-20, 200 μl cold GVBE was
added, the samples were centrifuged and the optical density of the supernatant was
determined at 414 nm. The percentage of lysis is graphed by subtracting the A414 of the
background lysis control, as well as the percentage of lysis induced by blocking CD59 alone
(~20%), and dividing this value by the maximum lysis obtained with water. The non-
significant (n.s.) differences between the ability of the wildtype rH19-20 versus each of the
mutants to induce lysis of EH (p>0.05) are indicated. The results are representative of two
separate experiments shown as means and standard deviations of triplicate observations.
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